$100M was Dowlings bull case for the year 2019 (Before FDA started with their warnings), realistically it's possible to achieve this in the next 12 months, due reasons laid out here many times, FDA, Covid CBD studies, new products etc.
Estimated Smokeless Tobacco Treatment Market for 2022 is $4B. If we would only get 10%, which is very conservative, that would bring us $400M per year revenue.
Closest competitor is Chantix, btw. who's patent is expiring in november 2020, that means Pfizer may now be interested in ours.
Chantix is on track to generate $1B revenue this year.